Due to the important role of PTP4A3 in cancers, a PRL-zumab was generated by the Zeng group and was shown to specifically inhibit PTP4A3-positive liver cancer cell in vivo, and recruit B cells, NK cells and macrophages to the PTP4A3-positive tumor microenvironment (27, 28). This evidence concerns the gene PTP4A3 and liver cancer.